Innventure Inc (INV) Stock News

A securities class action lawsuit has been filed against UWM Holdings Corporation for allegedly making materially false and misleading statements regarding its mortgage servicing rights (MSRs) hedging strategy and hedge position related to the Two Harbors transaction. The lawsuit claims the company deviated from its traditional non-hedging strategy, over-hedged its position, and created excess hedging risk while making positive statements about its business. Investors with losses exceeding $100K who purchased securities between March 9, 2026 and August 5, 2026 have until October 13, 2026 to seek appointment as lead plaintiff.

A class action lawsuit has been filed against Duolingo, Inc. alleging that the company made false statements about Daily Active User growth while deliberately adding friction through increased ads and subscription upsells. The lawsuit covers stock purchases between May 2, 2025 and February 26, 2026. Duolingo's stock declined significantly following revelations of slowing DAU growth (from 49% to 30%) and a strategic shift away from monetization, with stock falling 25%, 8.5%, and 14% on three separate disclosure dates.

A securities class action lawsuit has been filed against XTI Aerospace, Inc. for allegedly making materially false and misleading statements regarding undisclosed senior executive activities, Board review procedures, and disclosure controls. Investors who purchased XTIA securities between April 15, 2026 and August 17, 2026 have until October 27, 2026 to seek appointment as lead plaintiff.

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Endava plc on behalf of investors who purchased securities between September 4, 2025 and September 21, 2026. The lawsuit alleges that Endava made false and misleading statements regarding accounting treatment of customer and supplier agreements, failed to disclose delays in financial results, and concealed doubts about internal control effectiveness. The company's CFO was placed on administrative leave following an investigation by independent counsel. Endava's stock price declined 24.37% following the announcement.

Kirby McInerney LLP has filed securities fraud class action lawsuits against Anavex Life Sciences Corp. for allegedly making false statements and failing to disclose inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased securities between November 26, 2025 and August 28, 2026. Anavex's stock declined significantly following disclosures about the CEO's termination, delayed SEC filings, and material weaknesses in internal controls.

A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Innventure Inc., alleging the company made false statements about Accelsius' DarkNX AI data center project and overstated 2026 revenue targets. A Morpheus Research report in May 2026 revealed the DarkNX project was fabricated with no evidence of existence. Innventure subsequently suspended its revenue guidance and removed the DarkNX project from internal bookings in August 2026, causing the stock to plummet 55%. Investors who purchased securities between November 17, 2025 and August 13, 2026 may be eligible to participate in the class action with a deadline of October 27, 2026 to seek lead plaintiff status.

Block & Leviton is investigating Millrose Properties for potential securities fraud, alleging the company misled investors about its business dealings with Lennar. A report claimed Millrose purchased approximately $200 million of finished Lennar homes at above retail prices and is renting them at a loss. The stock declined following the report and a subsequent analyst downgrade.

Pomerantz LLP is investigating Deep Fission, Inc. for potential securities fraud following an Iceberg Research short report claiming the company's underground borehole reactor technology was overhyped and unlikely to achieve commercial viability. The stock fell 10.9% to $6.95 per share after the report's publication on September 26, 2026, just over three months after the company's IPO at $16.00 per share.

Pomerantz LLP is investigating potential securities fraud claims against Flutter Entertainment plc following the company's announcement on September 28, 2026, that it ceased operations in Brazil due to a nationwide online gaming ban. The news triggered a 7.93% stock price decline, with Flutter projecting approximately $70 million in lost 2026 revenue and $20 million reduction in adjusted EBITDA from the Brazilian unit closure.

Pomerantz Law Firm has filed a class action lawsuit against Fluence Energy, Inc. (NASDAQ: FLNC) alleging securities fraud and unlawful business practices. The lawsuit follows a series of disappointing financial announcements in 2026, including declining gross profit margins, significant revenue misses, and multiple guidance cuts totaling $1 billion in revenue reductions. The company's stock price fell dramatically following each announcement, dropping from $18.95 to $7.66 per share between February and September 2026. Investors have until November 30, 2026, to request Lead Plaintiff status.

Pomerantz LLP is investigating potential securities fraud claims against AirSculpt Technologies following a significant stock price decline of 45.11% on August 10, 2026, after the company reported lower-than-expected quarterly revenue of $42.9 million, down from $44.0 million year-over-year.

Pomerantz LLP is investigating potential securities fraud claims against Sionna Therapeutics following the company's August 10, 2026 announcement that its PreciSION CF Phase 2a trial failed to achieve its key activity endpoint. The failure to demonstrate efficacy of SION-719 when combined with Trikafta resulted in a dramatic 91.18% stock price decline, falling from approximately $51.04 to $4.50 per share.

Pomerantz LLP has launched investigations into potential securities fraud and unlawful business practices at Securitize Corp., Fluence Energy, Inc., and AirSculpt Technologies, Inc. The law firm is seeking investors who suffered losses to join class action lawsuits against these companies.

Pomerantz LLP is investigating potential securities fraud claims against Abeona Therapeutics following the company's August 13, 2026 disclosure that only four of five patient treatments with ZEVASKYN were recognized for revenue due to one batch lacking minimum sheet requirements. The announcement triggered a 14.95% stock price decline.

Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance.

Pomerantz LLP is investigating potential securities fraud claims against J.B. Hunt Transport Services following the company's September 16, 2026 warning of a 5-10% sequential earnings decline in Q3 2026. The decline was attributed to rising diesel fuel prices and a $25 million unexpected surge in driver expenses. The announcement triggered a 13.3% stock price drop, falling $36.52 to $236.73 per share.

Pomerantz Law Firm has filed a class action lawsuit against Endava Plc, alleging securities fraud and unlawful business practices. The lawsuit follows Endava's announcement that CFO Mark Thurston was placed on administrative leave pending an investigation into accounting treatment concerns raised by the company's auditors. Endava's stock price fell 24.37% on the news. The deadline to join the class action is November 30, 2026.

Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.

Pomerantz Law Firm has filed class action lawsuits against Papa John's International and Endava Plc, and is investigating claims against J.B. Hunt Transport Services. Papa John's stock fell 17.18% after announcing an 8.3% decrease in North American comparable sales, dividend suspension, and reduced 2026 guidance. Investors with losses are urged to contact the firm by November 2, 2026.

Pomerantz LLP is investigating Zscaler, Inc. for potential securities fraud following two significant stock price declines. The first occurred on May 27, 2026, when the stock fell 31.52% after the company issued lower-than-expected guidance for current-quarter revenue. The second decline of 10.06% happened on September 25, 2026, following the announcement of Chief Revenue Officer Mike Rich's departure. Investors are invited to join the class action lawsuit.

Pomerantz LLP announced investigations into potential securities fraud and unlawful business practices at OSI Systems, lululemon athletica, and Ultragenyx Pharmaceutical. The investigation into OSI was triggered by the company's August 20, 2026 earnings report that missed revenue expectations due to deferred product deliveries, resulting in a 5.21% stock price decline.

Pomerantz LLP is investigating potential securities fraud claims against lululemon athletica following the company's September 3, 2026 earnings report, which revealed lower-than-expected revenue, sharply reduced full-year guidance, and negative media commentary. The stock fell 17.38% to $100.61 per share on September 4, 2026.

Pomerantz LLP announced investigations into potential securities fraud at Ultragenyx Pharmaceutical, OSI Systems, and lululemon athletica. The investigation into Ultragenyx was triggered by the company's failure to meet primary endpoints in a Phase 3 clinical trial for apazunersen, resulting in a 44% stock price decline on September 3, 2026.

Pomerantz LLP is investigating Stryker Corp. for potential securities fraud following the CEO's disclosure on September 8, 2026, that a manufacturing problem in the peripheral vascular business would persist into Q4 2026 instead of resolving in Q3 as previously stated. The announcement triggered an 8.81% stock price decline, falling $26.70 per share to $276.43.

Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026.

Rosen Law Firm is urging AppLovin Corporation investors who purchased securities between February 12, 2026 and August 5, 2026 to join a class action lawsuit. The lawsuit alleges that AppLovin made false statements about its generative AI video creative feature, overstated AI model improvements, and misrepresented the benefits of its 'virtuous cycle' value proposition. The lead plaintiff deadline is November 16, 2026.

A securities class action lawsuit has been filed against FuelCell Energy, Inc. (FCEL) for allegedly making false and misleading statements regarding manufacturing capacity, production rates, and profitability. The lawsuit covers purchases between June 24, 2026 and September 1, 2026, with a lead plaintiff deadline of November 10, 2026. Investors who purchased FCEL securities during this period may be eligible for compensation.

Rosen Law Firm reminds investors who purchased Flotek Industries (FTK) securities between August 3-17, 2026 of the October 26, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges defendants made false statements about a Puerto Rico Electric Power Authority contract, failing to disclose credibility concerns about consortium parties and risks to revenue realization.

A securities class action lawsuit has been filed against DICK'S Sporting Goods, Inc. (DKS) for allegedly making materially false and misleading statements regarding its business operations. The lawsuit claims the company failed to disclose incomplete cleanup efforts from the Foot Locker acquisition, exposure to excess inventory, and promotional pressures that prevented achievement of promised sales growth and profits. Investors who purchased DKS stock between September 8, 2025 and August 24, 2026 may be eligible for compensation. The lead plaintiff deadline is November 3, 2026.